Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Background Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) 

Saved in:
Bibliographic Details
Published in:Irish journal of medical science 2024-04, Vol.193 (2), p.833-836
Main Authors: Buckley, Frances D., Arnold, Claire, Brass, Dawn, Catherwood, Mark, McMullin, Mary Frances
Format: Article
Language:English
Subjects:
Brief Report
Family Medicine
General Practice
Internal Medicine
Medicine
Medicine & Public Health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) 
ISSN:0021-1265
1863-4362
DOI:10.1007/s11845-023-03510-7